Compare DexCom, Inc. (DXCM) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Newmont Corporation — how do they compare? DexCom, Inc. trades at $83.36 (market cap $31.86B), while Newmont Corporation trades at $118.39 (market cap $121.75B). The key difference: Newmont Corporation is far larger — about 3.8× DexCom, Inc.'s market cap, and Newmont Corporation pays a 0.9% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | NEM | |
|---|---|---|
Market Cap | $31.86B | $121.75B |
Volume | 3,607,070 | 5,421,125 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $135.14 |
52-Week Low | $54.84 | $78.63 |
Typical Hold Time | 62 Days | — |
Enterprise Value | $31.32B | $118.34B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Newmont (NEM) trades at $118.23, up 4.13% today, supported by strong earnings beats and record free cash flow. The stock shows a bearish technical signal near key support at $114, while fundamentals are robust with a P/E of 14.57, net income margin of 33.36%, and revenue growth to $22.67B in 2025. Analyst consensus is strongly bullish with a $136.83 price target.
The outlook for NEM is positive, driven by operational improvements and a constructive gold market. Key risks include gold price volatility and execution of growth projects. With no analyst sell ratings and strong institutional interest, the stock presents a compelling opportunity for investors seeking exposure to a leading gold producer.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
